Best Immunotherapy Companies in Houston, United States

Developer of T-cell based therapeutics for cancer treatment. The company's lead product candidates are used against triple-negative breast cancer and ovarian cancer. The company is also developing peptide vaccines for the treatment purpose.

Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies. The company focuses on developing innovative treatments by leveraging the unique metabolic signatures of cancer and immune cells. Their lead molecule targets Oxidative Phosphorylation, aiming to decrease aberrant cell growth and proliferation in targeted cancer cells and fibrosis. They are developing a library of biguanides with the potential for development as novel treatments for cancer and/or diseases of fibrosis. The company is dedicated to advancing science and improving patient outcomes through targeted therapeutic interventions in oncology and fibrosis. They are a clinical stage company.

Funding rounds

• Jan 2026Series B$842.2K
• Mar 2017Series B$5M
• Mar 2016Series A$5.2M

Founders & team

Dean WelschCEO

Investors

NHN Investment, SL Investment Management, Mirae Asset Venture, InterVest, JLABS, GNTech Venture Capital

Developer of immunotherapeutics for the treatment of cancer. It offers a pipeline of drug candidates based on T regulatory cells and a small molecule inhibitor that blocks the transcriptional activity in cancer cells. It provides drugs for breast, lung, prostate, colorectal, and pancreatic cancer treatment.

Funding rounds

• Apr 2025Series C$62.6M
• Jan 2025Series B$20.8M
• Feb 2024Series B$14.5M
• Aug 2022Series B$12.9M

Founders & team

Steve GorlinCEO

Investors

Kizoo

Provider of immunotherapeutics for cancer treatment. It offers Dendritic Cell Vaccines for Glioblastoma, Pancreatic cancer, Sarcoma, Intratumoral Injection for Bone Cancer, Head and Neck Cancer, and CAR T cell therapies for HER 2+ Breast Cancer, and solid tumors.

Funding rounds

• Jun 2025Seed$20M
• Aug 2024Seed$11.4M

Founders & team

Mike WicksCEO

Investors

Restem, Baylor College of Medicine, Brain Tumor Investment Fund, Buttonwood Titan QC Fund

Tech stack

CdnjsCloudflareCloudflare Bot ManagementCore-JsFancyboxGoogle Analytics

Developer of medicines for cancer, autoimmune, and infectious diseases. The company's lead antibody, ASY-77A, enhances antigen presentation by targeting the extracellular form of heat shock protein. Another candidate ASY-77A has produced complete regression of various cancer types including solid tumors such as breast and colon cancer, and blood-related cancers like multiple myeloma.

Funding rounds

• Apr 2025Grant (prize money)$241.4K
• Apr 2022Grant (prize money)$246.5K
• Mar 2021Series A$14.5M

Founders & team

Richard JonesCo-FounderRobert Z OrlowskiFounderRonald A DePinhoCo-Founder

Investors

Sporos Bioventures, HHS

Developer of immunotherapies to treat cancer. The company's lead immunotherapy, MEM-288, is to treat patients with advanced cancers including lung, breast, pancreatic, and prostate cancers. Other candidates include MEM 40 to treat COVID-19.

Stingray Therapeutics is developing immune-oncology therapies for treating cancer. The oral medicines developed are used to stimulate the innate immune system and block adaptive immune-suppressive proteins. The checkpoint inhibitors are used to inhibit the ENPP1 to prevent blocking of innate immunity (T-cells and antibodies) from killing the cancer cells.

Funding rounds

• Feb 2025Grant (prize money)$3.5M
• Jan 2023Series A$6.6M
• Sep 2022Grant (prize money)$2M
• May 2021Seed$1.5M

Founders & team

Sunil SharmaCo-FounderJon NorthrupCo-Founder & CEO

Investors

Health Wildcatters, HHS, Cavendish Impact Foundation, Catalytic Impact Foundation

Developer of interleukin-4 Receptor (IL4R) targeted cytokines for cancer. Its lead product MDNA55 is in clinical development (phase 2 trials) for the treatment of CNS and urological cancers. It designs a class of multi-targeted fusion proteins called IL4-ECs which harness the specificity and affinity of engineered cytokines (Superkines) to selectively deliver cell-killing Payloads to the bulk tumor, tumor microenvironment (TME), and cancer stem cells (CSC).

Developer of immunotherapeutic cancer treatments targeting HLA‑G antigen. The company specializes in developing CAR‑T cell therapies and monoclonal antibody treatments that target the HLA‑G immune checkpoint antigen commonly expressed by solid tumors. It operates clinical‑stage programs focused on anti‑HLA‑G and telomerase‑based platforms for restoring anti‑tumor immune function. The lead candidate is an anti‑HLA‑G CAR‑T therapy currently in early clinical trials in solid tumors. The company collaborates with academic and manufacturing institutions to scale process development and manufacturing workflows for clinical use.

Funding rounds

• Sep 2024Series A$4M
• Mar 2023Grant (prize money)$301.5K
• Oct 2018Series A$17.1M
• Jul 2017Series A$4.9M

Founders & team

Simon Wain-HobsonCo-Founder & CSOPierre DemoyenCo-Founder & Co-CEOJake KushnerCo-CEO

Investors

Bpifrance, Europa

Tech stack

WordpressMysqlPhpGoogle MapsResponsive Lightbox & GalleryContact Form 7

Developer of therapeutics against lung infections. The lead candidate PUL-042 is an inhalant that stimulates the innate immune system in the lungs, protecting against a wide range of inhaled pathogens. It claims that the candidate has shown to protect against bacterial, fungal, and viral pathogens.

Developer of therapeutics for cell therapy and exosome therapy. The company developed various products such as ALS 001 and EXO 001 for Amyotrophic Lateral Sclerosis, FTD 080 and EXO O50 for Frontotemporal Dementia, and AID 912 for Scleroderma.

{}